EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus ErythematosusPRNewsWire • 06/03/20
Coronavirus Treatment Search Still on, Lilly, Gilead Give UpdatesZacks Investment Research • 06/02/20
Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'Benzinga • 06/01/20
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus ImmunityZacks Investment Research • 06/01/20
Eli Lilly begins early-stage human testing of its experimental antibody-based COVID-19 vaccineInvezz • 06/01/20
Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)PRNewsWire • 06/01/20
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in HumansPRNewsWire • 06/01/20
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's LymphomaPRNewsWire • 05/31/20
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaPRNewsWire • 05/31/20
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung CancerPRNewsWire • 05/30/20
3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020Zacks Investment Research • 05/28/20
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarctionPRNewsWire • 05/26/20